Business
ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on
About this update from Oric Pharmaceuticals, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple poster presentations highlighting preclinical data from the company’s glucocorticoid receptor (GR) antagonist and CD73 inhibitor programs will be presented at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020.\n Details of the planned presentations are as follows: ORIC-101 (GR Antagonist) Poster Presentations:Title: ORIC-101 comprehensively inhibits glucocorticoid pathways to overcome therapeutic resistance in pan-cancer models Date: June 22, 2020Session: Mechanisms of Sensitivity and Resistance to Targeting Hormone Responsive CancerAbstract: 4120 Title: ORIC-101 overcomes resistance to diverse chemotherapeutics across cancer types Date: June 22, 2020Session: Mechanisms of Sensitivity and Resistance to Targeting Hormone Responsive CancerAbstract: 4121 Title: ORIC-101 overcomes glucocorticoid receptor-mediated chemoresistance in pancreatic cancer models Date: June 22, 2020Session: Mechanisms of Sensitivity and Resistance to Targeting Hormone Responsive CancerAbstract: 4123 ORIC-533 (CD73 Inhibitor) Poster Presentations:Title: CD73 inhibition with a novel orally bioavailable small molecule blocks adenosine production and rescues T-cells activation Date: June 22, 2020Session: Tumor Induced Immune SuppressionAbstract: 1023 Title: An orally bioavailable inhibitor of CD73 reverts intratumoral immunosuppression and promotes anti-tumor responses Date: June 22, 2020Session: Late-Breaking Research: Experimental and Molecular Therapeutics 2Abstract: LB-115 About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-pacli...